| 25.105 -0.335 (-1.32%) | 04-24 15:16 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 31.82 | 1-year : | 34.8 |
| Resists | First : | 27.24 | Second : | 29.79 |
| Pivot price | 25.67  |
|||
| Supports | First : | 23.11 | Second : | 19.22 |
| MAs | MA(5) : | 24.61  |
MA(20) : | 26.32 |
| MA(100) : | 21 |
MA(250) : | 14.82 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 35.3 |
D(3) : | 25.8 |
| RSI | RSI(14): 47.1 |
|||
| 52-week | High : | 30.26 | Low : | 6.4 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ DYN ] has closed above bottom band by 41.1%. Bollinger Bands are 14.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 26.36 - 26.46 | 26.46 - 26.56 |
| Low: | 24.57 - 24.69 | 24.69 - 24.81 |
| Close: | 25.25 - 25.43 | 25.43 - 25.61 |
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Wed, 24 Apr 2024
Brokerages Set Dyne Therapeutics, Inc. (NASDAQ:DYN) Price Target at $37.43 - MarketBeat
Mon, 25 Mar 2024
Dyne Therapeutics Announces CEO Transition - GlobeNewswire
Tue, 05 Mar 2024
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights - Yahoo Finance
Wed, 21 Feb 2024
Dyne Therapeutics: An Updated Analysis (NASDAQ:DYN) - Seeking Alpha
Fri, 26 Jan 2024
Dyne Therapeutics stock jumps amid report of takeover interest - Seeking Alpha
Fri, 26 Jan 2024
Chief Business Officer Jonathan Mcneill Sells 20,000 Shares of Dyne Therapeutics Inc (DYN) - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 86 (M) |
| Shares Float | 53 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 86.5 (%) |
| Shares Short | 8,080 (K) |
| Shares Short P.Month | 6,610 (K) |
| EPS | -3.96 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.49 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -64.3 % |
| Return on Equity (ttm) | -137.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -188 (M) |
| Levered Free Cash Flow | -104 (M) |
| PE Ratio | -6.4 |
| PEG Ratio | 0 |
| Price to Book value | 16.95 |
| Price to Sales | 0 |
| Price to Cash Flow | -11.58 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|